Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

NEON vs NERV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

NERV Captures Overall Composite Edge (43.3 HOLD vs 39.8 SELL), While NEON Leads 4–1 on Growth & Valuation Pillars

NERV Overall Winner 6-Pillar Tally: NEON 4 – 1 NERV (1 Tie) Matrix Metrics: NEON 5 – 5 NERV

As of Nov 20, 2026, Minerva Neurosciences, Inc (NERV) captures the overall head-to-head institutional edge over Neonode Inc. (NEON) on higher Unified Composite conviction (43.3/100 HOLD vs. 39.8/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale), while NEON wins 4–1 across the 6-pillar growth and valuation breakdown. NEON trades at $0.48 (9.3x Forward P/E, -604.4% operating margin) versus NERV at $2.00 (11.2x Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: NERV earns the overall head-to-head edge with a stronger Unified Composite Score (43.3/100 HOLD vs. NEON 39.8/100 SELL) and 1.63β · 76% Vol risk profile, whereas NEON leads top-line expansion (-20.4% YoY revenue growth, 0.37x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: NEON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.0); meanwhile NERV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NEON vs NERV
NEON NASDAQ
Neonode Inc. Common Stock
Electronic Components, Nec
$0.48
-7.69% 1D
Market Cap $8.7M
TTM Revenue $2.0M
Forward P/E 9.3x
Beta / 30D Vol 2.07β · 63% Vol
Unified Composite Score
39.8 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 22
RSI-14: 22.0 · SMA20: $0.63 · SMA50: $0.76
NERV NASDAQ Head-to-Head Winner
Minerva Neurosciences, Inc
Pharmaceutical Preparations
$2.00
-5.66% 1D
Market Cap $105.7M
TTM Revenue N/A
Forward P/E 11.2x
Beta / 30D Vol 1.63β · 76% Vol
Unified Composite Score
43.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -24.9%), weak momentum, RSI 33
RSI-14: 33.5 · SMA20: $2.31 · SMA50: $2.80

6-Pillar Scorecard Institutional Category Breakdown (NEON 4 – 1 NERV)

Columns: Metric · NEON · NERV
1. Valuation Multiples NEON
Forward P/E 9.3x 11.2x
Trailing P/E 9.3x 11.2x
PEG Ratio 0.37x N/M
EV / Revenue N/M N/M
2. Growth & Scale NERV
Revenue Growth (YoY) -20.4% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $2.0M N/A
Market Cap $8.7M $105.7M
3. Profitability & Quality NEON
Gross Margin 98.8% N/A
Operating Margin -604.4% 0.0%
Net Profit Margin 397.8% 0.0%
Return on Equity (ROE) 46.8% -675.1%
4. Balance Sheet & Cash Flow NEON
Cash Generation (TTM) -$11M -$31M
Cash Flow Margin N/A N/A
Net Cash / Leverage $23M Net Cash -675.1% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NEON
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 77.8% (50th %ile) 194.3% (100th %ile)
Put/Call OI Skew N/A 6.67x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Electronic Components Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NEON (5) vs NERV (5)
Institutional Metric NEON NERV Criterion Row Edge
Market Capitalization
Scale
$8.7M $105.7M Larger Scale NERV
Trailing P/E Ratio
Valuation
9.3x 11.2x Lower Multiple NEON
Forward P/E Ratio
Valuation
9.3x 11.2x Lower Multiple NEON
Revenue Growth (YoY)
Growth
-20.4% +0.0% Higher Growth NERV
Operating Margin (TTM)
Profitability
-604.4% 0.0% Higher Margin NERV
Net Profit Margin
Profitability
397.8% 0.0% Higher Margin NEON
Return on Equity (ROE)
Capital Efficiency
46.8% -675.1% Higher ROE NEON
52-Week Range Position
Momentum
0% ($0–$2) 1% ($2–$9) Stronger Trend NERV
Beta / 30D Volatility
Risk Regime
2.07β · 63% Vol 1.63β · 76% Vol Lower Realized Risk NEON
Unified Institutional Score
Composite Signal
39.8 / 100 (SELL) 43.3 / 100 (HOLD) Higher Composite NERV
Trailing 12M Revenue (USD)
Operating Scale
$2.0M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
98.8% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.37x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M ($23M Net Cash) -$31M (-675.1% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NERV +19.54 pp
NEON: -36.21% · NERV: -16.67%
3M Horizon NEON +11.93 pp
NEON: -46.49% · NERV: -58.42%
6M Horizon NERV +11.2 pp
NEON: -73.18% · NERV: -61.98%
1Y Horizon NERV +22.75 pp
NEON: -76.24% · NERV: -53.49%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NEON vs NERV. Trailing 12-month operating profitability (NEON -604.4% vs NERV 0.0%) and valuation multiples (NEON 9.3x vs NERV 11.2x Forward P/E) are benchmarked directly in Pillar 4 below.

NEON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.0M
Gross Margin98.8%
Op. Margin-604.4%
ROE / Fwd P/E46.8% · 9.3x
NERV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-675.1% · 11.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NEON UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 77.8%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NEON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NERV BREAKDOWN
148d in phase · OBV DISTRIBUTION
Current IV 194.3%
IV Percentile 100th %ile
Put/Call OI Skew 6.67x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow DISTRIBUTION
Exact NERV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NEON Moat Profile High-Margin Pricing Power Moat
Electronic Components Operator
Competes within the Electronic Components value chain with $8.7M market capitalization and -604.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NERV Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $105.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ NEON vs NERV Key Questions & Quantitative Answers

As of Nov 20, 2026, Minerva Neurosciences, Inc (NERV) captures the overall head-to-head institutional edge over Neonode Inc. (NEON) on higher Unified Composite conviction (43.3/100 HOLD vs. 39.8/100 SELL) after splitting the core matrix 5–5 (led by Growth & Scale), while NEON wins 4–1 across the 6-pillar growth and valuation breakdown. NEON trades at $0.48 (9.3x Forward P/E, -604.4% operating margin) versus NERV at $2.00 (11.2x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: NERV earns the overall head-to-head edge with a stronger Unified Composite Score (43.3/100 HOLD vs. NEON 39.8/100 SELL) and 1.63β · 76% Vol risk profile, whereas NEON leads top-line expansion (-20.4% YoY revenue growth, 0.37x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: NEON is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 22.0); meanwhile NERV is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

NERV leads the Growth & Scale pillar: NEON posts -20.4% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (98.8% gross margin, -604.4% operating margin), compared with NERV at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NEON generates $2.0M in USD-normalized revenue versus N/A for NERV. In operating R&D and SG&A reinvestment, NEON deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NERV.

NEON screens cheaper on headline valuation multiples. NEON trades at 9.3x Forward P/E, 9.3x Trailing P/E, 0.37x PEG, and N/M EV/Revenue (unreported FCF margin), whereas NERV trades at 11.2x Forward P/E, 11.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEON (46.8% ROE) versus NERV (-675.1% ROE) capital efficiency.

In options market volatility and institutional positioning, NEON carries 77.8% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 63% Vol realized risk). By comparison, NERV carries 194.3% implied volatility (100th %ile, Extreme (>80th %ile)), a 6.67x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.63β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.